Programmed cell death protein 1 on natural killer cells: fact or fiction?

Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 2020-06, Vol.130 (6), p.2816-2819
Main Authors: Cho, Monica M, Quamine, Aicha E, Olsen, Mallery R, Capitini, Christian M
Format: Article
Language:English
Subjects:
Animals
Apoptosis
B7-H1 Antigen
Biochemistry
Cancer research
Cancer treatment
Dogs
Humans
Immunotherapy
Killer cells
Killer Cells, Natural
Mice
Nivolumab
Pembrolizumab
Programmed Cell Death 1 Receptor - genetics
T cells
T-Lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been controversial, with papers publishing contradictory results in multiple models, there is increased clinical interest in NK and PD-1 immunotherapy. In this issue of the JCI, Judge et al. comprehensively explore the lack of PD-1 expression on murine, canine, and human NK cells and the clinical implication of these findings.
ISSN:0021-9738
1558-8238
DOI:10.1172/JCI137051